KRAS and non-small cell lung carcinoma: It might be expected that the survival outcome is better in the subgroup of patients with mutations in light of targeted therapies; however, approximately 45% of patients had either TP53 or KRAS mutations, which have been shown in multiple studies to indicate poorer outcomes in NSCLC.